Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

We report the outcome of 229 patients who received an allograft for myeloma with reduced-intensity conditioning (RIC) regimens from 33 centers within the European Group for Blood and Marrow Transplantation (EBMT). The median age was 52 years and 64% were male. Conditioning regimens were heterogeneous, but most were fludarabine based and T cell depleted with antithymocyte globulin or alemtuzumab. Transplantation-related mortality (TRM) at 1 year was 22%. The 3-year overall survival (OS) and progression-free survival (PFS) were 41% and 21%, respectively. Adverse OS was associated with chemoresistant disease (relative risk [RR], 2.9), more than 1 prior transplantation (RR, 2.0), and male patients with female donors (RR, 1.45). Adverse PFS was associated with chemoresistance (RR, 2.4) and alemtuzumab (RR, 1.8). TRM was increased with female-to-male donation (RR, 2.5) and transplantation more than 1 year from diagnosis (RR, 2.3). Grades II to IV acute graft-versus-host disease (aGvHD) occurred in 31%. Chronic GvHD was associated with better OS and PFS and were 84% and 46% for limited, 58% and 30% for extensive, and 29% and 12% in its absence suggesting that a graft-versus-myeloma effect is important. While RIC is feasible, heavily pretreated patients and patients with progressive disease do not benefit.

[1]  H. Einsele,et al.  Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. , 2004, Blood.

[2]  F. Appelbaum,et al.  Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. , 2004, Blood.

[3]  R. Storb,et al.  Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. , 2003, Blood.

[4]  M. Maris,et al.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.

[5]  H. Einsele,et al.  Follow‐up of patients with progressive multiple myeloma undergoing allografts after reduced‐intensity conditioning , 2003, British journal of haematology.

[6]  S. Mackinnon,et al.  Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  J. S. San Miguel,et al.  Chronic but not acute graft‐versus‐host disease improves outcome in multiple myeloma patients after non‐myeloablative allogeneic transplantation , 2003, British journal of haematology.

[8]  K. Busam,et al.  Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. , 2003, Blood.

[9]  A. Gratwohl,et al.  Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey , 2002, Bone Marrow Transplantation.

[10]  N. Schmitz,et al.  Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. , 2002, Blood.

[11]  N. Ueno,et al.  Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma , 2002, Bone Marrow Transplantation.

[12]  N. Kröger,et al.  Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. , 2002, Blood.

[13]  B. Barlogie,et al.  Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Solano,et al.  Allogeneic peripheral blood stem cell transplantation with reduced‐intensity conditioning: results of a prospective multicentre study , 2001, British journal of haematology.

[15]  G. Sauvageau,et al.  Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect , 2001, Bone Marrow Transplantation.

[16]  C Anasetti,et al.  Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. , 2001, Blood.

[17]  J. Gribben,et al.  T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. , 2001, Blood.

[18]  G. Gahrton,et al.  Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres , 2001, British journal of haematology.

[19]  T. Braun,et al.  Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma , 2001, Bone Marrow Transplantation.

[20]  G. Morgan,et al.  In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. , 2000, Blood.

[21]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[22]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[23]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[24]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.

[25]  R. Marcus,et al.  Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. , 1996, Blood.

[26]  R. Storb,et al.  Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. , 1996, Blood.

[27]  H. Deeg,et al.  Bone marrow transplantation in patients aged 45 years and older. , 1986, Blood.